Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
about
How grim is hepatocellular carcinoma?A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.Systemic chemotherapy of liver tumors.Primary liver tumors.Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.Systemic therapies for hepatocellular carcinoma.Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma.Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma.Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha.Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Evolution of systemic therapy of advanced hepatocellular carcinoma.Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombusReview article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
P2860
Q27001669-073A3E3B-D72E-4BC4-B91D-5E69F5DF16BCQ33493146-149BCA5F-5F92-4511-BEA9-D5F3BB360AB8Q34110952-3F9AFC91-CFAE-4BDE-AD75-4A4B83FA0AA3Q34110964-1773FDBA-06C8-459F-ABB4-CD0C7ADAB482Q34998414-63B03A65-5E9B-4BD0-8885-42EA9A131816Q35964708-9DE9BAC3-35A8-4778-8932-C9A14C26CD73Q36671639-F574A045-995D-4F09-8A59-1B1FCCEEE883Q36945072-1BD21916-6F44-41F0-90C6-3C0CC5AE8F34Q38056849-DAEAA9B6-1F27-469F-961B-41B04C3A57E8Q38625948-94D468C5-4E91-455B-B962-4C9A2F30EF75Q40558434-27EC08E9-1A36-4537-84C1-EB9E5AAB90EFQ41814612-843AEFA8-15D2-4AFD-B218-4E381869A5A6Q42343451-554C6C86-CD67-4CA8-8AC4-1D4A7DF42D24Q42617015-A5E69892-8CF7-4844-8E2A-6CD27DF74F23Q42726305-FB846E3C-33B1-4F32-9902-E29C79E4F13FQ47734769-90E74CD9-F5C2-4FE3-AB58-6ECE340CA331Q47869247-B859C555-035D-4E33-BE3C-7ED43EAC0334Q54234543-56262312-FEB6-488B-B324-679C7D2352D8Q58236397-205F8239-79C5-4AA4-939D-F1C7B0CF02BC
P2860
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Recombinant alpha 2 interferon ...... prospective randomised trial.
@ast
Recombinant alpha 2 interferon ...... prospective randomised trial.
@en
type
label
Recombinant alpha 2 interferon ...... prospective randomised trial.
@ast
Recombinant alpha 2 interferon ...... prospective randomised trial.
@en
prefLabel
Recombinant alpha 2 interferon ...... prospective randomised trial.
@ast
Recombinant alpha 2 interferon ...... prospective randomised trial.
@en
P2093
P2860
P356
P1476
Recombinant alpha 2 interferon ...... prospective randomised trial.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1989.392
P407
P577
1989-12-01T00:00:00Z